Compare Sanofi India with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ALKEM LABORATORIES - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ALKEM LABORATORIES SANOFI INDIA/
ALKEM LABORATORIES
 
P/E (TTM) x 41.0 22.2 184.9% View Chart
P/BV x 8.3 5.3 156.0% View Chart
Dividend Yield % 1.0 0.9 115.1%  

Financials

 SANOFI INDIA   ALKEM LABORATORIES
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
ALKEM LABORATORIES
Mar-20
SANOFI INDIA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6,8402,720 251.5%   
Low Rs4,6301,660 278.9%   
Sales per share (Unadj.) Rs1,203.1697.9 172.4%  
Earnings per share (Unadj.) Rs165.396.1 171.9%  
Cash flow per share (Unadj.) Rs209.9117.3 179.0%  
Dividends per share (Unadj.) Rs84.0025.00 336.0%  
Dividend yield (eoy) %1.51.1 128.3%  
Book value per share (Unadj.) Rs963.6515.2 187.0%  
Shares outstanding (eoy) m23.03119.57 19.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.83.1 151.9%   
Avg P/E ratio x34.722.8 152.3%  
P/CF ratio (eoy) x27.318.7 146.3%  
Price / Book Value ratio x6.04.3 140.0%  
Dividend payout %50.826.0 195.4%   
Avg Mkt Cap Rs m132,078261,879 50.4%   
No. of employees `0003.314.3 23.0%   
Total wages/salary Rs m4,06815,055 27.0%   
Avg. sales/employee Rs Th8,393.85,822.6 144.2%   
Avg. wages/employee Rs Th1,232.41,050.5 117.3%   
Avg. net profit/employee Rs Th1,153.0802.0 143.8%   
INCOME DATA
Net Sales Rs m27,70883,444 33.2%  
Other income Rs m8971,042 86.1%   
Total revenues Rs m28,60584,486 33.9%   
Gross profit Rs m6,23514,734 42.3%  
Depreciation Rs m1,0272,528 40.6%   
Interest Rs m7651 1.1%   
Profit before tax Rs m6,09812,598 48.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2921,105 207.5%   
Profit after tax Rs m3,80611,493 33.1%  
Gross profit margin %22.517.7 127.4%  
Effective tax rate %37.68.8 428.6%   
Net profit margin %13.713.8 99.7%  
BALANCE SHEET DATA
Current assets Rs m15,92254,960 29.0%   
Current liabilities Rs m6,23532,433 19.2%   
Net working cap to sales %35.027.0 129.5%  
Current ratio x2.61.7 150.7%  
Inventory Days Days6480 80.0%  
Debtors Days Days2172 28.9%  
Net fixed assets Rs m7,53932,710 23.0%   
Share capital Rs m230239 96.2%   
"Free" reserves Rs m21,96261,368 35.8%   
Net worth Rs m22,19261,607 36.0%   
Long term debt Rs m01,592 0.0%   
Total assets Rs m29,83999,433 30.0%  
Interest coverage x872.120.4 4,282.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.8 110.7%   
Return on assets %12.812.2 104.6%  
Return on equity %17.218.7 91.9%  
Return on capital %27.521.0 131.2%  
Exports to sales %019.1 0.0%   
Imports to sales %03.0 0.0%   
Exports (fob) Rs mNA15,917 0.0%   
Imports (cif) Rs mNA2,483 0.0%   
Fx inflow Rs m7,58716,061 47.2%   
Fx outflow Rs m7,1452,483 287.8%   
Net fx Rs m44213,578 3.3%   
CASH FLOW
From Operations Rs m3,7395,851 63.9%  
From Investments Rs m-731-7,414 9.9%  
From Financial Activity Rs m-1,972792 -249.1%  
Net Cashflow Rs m1,036-731 -141.7%  

Share Holding

Indian Promoters % 0.0 66.9 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 33.1 43.5%  
FIIs % 14.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 0.0 -  
Shareholders   15,184 68,381 22.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ORCHID PHARMA  CIPLA  ASTRAZENECA PHARMA  AUROBINDO PHARMA  STERLING BIOTECH  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Apr 13, 2021 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS